“Ultimovacs starter fase 2-studie for pasienter med alvorlig eggstokkreft – rekrutterer norske pasienter Ultimovacs har i den siste tiden startet […]
Other News |
Press Releases
QuickView company update on Ultimovacs has been published by Edison Investment Research (company sponsored research)
Ultimovacs – Phase II data from 500+ patients over 2022/23
Biostock article: Ultimovacs announces collaboration with AstraZeneca
“Ultimovacs announced yesterday that it will be participating in a phase II study in collaboration with AstraZeneca, along with the […]
HealthTalk Norge with an article about FOCUS, Ultimovacs’ fourth phase II trial
“Ultimovacs går nå i gang med en fase 2 studie som skal undersøke effekten av å legge kreftvaksinen UV1 til […]
BioStock has published the article: “Ultimovacs initiates fourth phase II trial with UV1”
“Christmas came a few days early for Ultimovacs as the company was able to announce the initiation of its fourth […]
Ticker on Oslo Børs changed to ULTI
The company ticker on Oslo Børs has now changed from ULTIMO to ULTI.
Full version of the publication in ‘Frontiers in Immunology’ featuring positive results from Phase I trial evaluating UV1 in Non-Small Cell Lung Cancer is now available
In referanse to the Stock Exchange announcement on 2 November 2020 (below) where an abstract of the publication was available. […]
BioStock has done a piece on Ultimovacs’ main advancements in the Q3-2020 period
“Ultimovacs is developing a universal cancer vaccine with the aim of inducing an immune response in cancer patients that is […]
Interview with Carlos de Sousa in Nordic Life Science magazine
“In June this year, Carlos de Sousa commenced his role as Chief Executive Officer of Norwegian Ultimovacs, a pharmaceutical company […]
Sara Mangsbo recieves 2020 SITC Team Science Award
As SITC celebrates 35 years of advancing the field of cancer immunotherapy, they want to recognize and honor those that […]